MX356411B - Derivados del tipo del azaindazol o diazaindazol como medicamento. - Google Patents

Derivados del tipo del azaindazol o diazaindazol como medicamento.

Info

Publication number
MX356411B
MX356411B MX2013008673A MX2013008673A MX356411B MX 356411 B MX356411 B MX 356411B MX 2013008673 A MX2013008673 A MX 2013008673A MX 2013008673 A MX2013008673 A MX 2013008673A MX 356411 B MX356411 B MX 356411B
Authority
MX
Mexico
Prior art keywords
same
azaindazole
medicament
derivatives
mixture
Prior art date
Application number
MX2013008673A
Other languages
English (en)
Other versions
MX2013008673A (es
Inventor
Kruczynski Anna
Perez Michel
Bachir Kaloun El
Bedjeguelal Karim
Rabot Rémi
Schmitt Philippe
Rahier Nicolas
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2013008673A publication Critical patent/MX2013008673A/es
Publication of MX356411B publication Critical patent/MX356411B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Abstract

La presente invención se relaciona con un compuesto de la siguiente fórmula (I) : o una sal o solvato farmacéuticamente aceptable del mismo, o un estereoisómero o mezcla de estereoisómeros del mismo en cualquier proporción, como una mezcla de enantiómeros, de manera notable, una mezcla racémica; así como con el uso del mismo como un principio activo, que se pretende sirva, de manera notable, para el tratamiento del cáncer, inflamación, y enfermedades neurodegenerativas como la enfermedad de as Alzheimer; con uso del mismo como inhibidor de cinasa; con las composiciones farmacéuticas que comprenden el mismo; y con los métodos para la preparación del mismo.
MX2013008673A 2011-01-27 2012-01-27 Derivados del tipo del azaindazol o diazaindazol como medicamento. MX356411B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (2)

Publication Number Publication Date
MX2013008673A MX2013008673A (es) 2013-12-02
MX356411B true MX356411B (es) 2018-05-24

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008673A MX356411B (es) 2011-01-27 2012-01-27 Derivados del tipo del azaindazol o diazaindazol como medicamento.

Country Status (30)

Country Link
US (2) US20130172360A1 (es)
EP (1) EP2668184B1 (es)
JP (1) JP5931926B2 (es)
KR (2) KR20180122028A (es)
CN (1) CN103339129B (es)
AR (1) AR084935A1 (es)
AU (1) AU2012210467B2 (es)
CA (1) CA2823824C (es)
CY (1) CY1120088T1 (es)
DK (1) DK2668184T3 (es)
ES (1) ES2661695T3 (es)
FR (1) FR2970967B1 (es)
HK (1) HK1186737A1 (es)
HR (1) HRP20180524T1 (es)
HU (1) HUE037153T2 (es)
IL (2) IL227496B (es)
LT (1) LT2668184T (es)
MA (1) MA34903B1 (es)
MX (1) MX356411B (es)
MY (1) MY180666A (es)
PL (1) PL2668184T3 (es)
PT (1) PT2668184T (es)
RS (1) RS57101B1 (es)
RU (1) RU2600976C2 (es)
SI (1) SI2668184T1 (es)
TN (1) TN2013000293A1 (es)
TR (1) TR201802944T4 (es)
TW (1) TWI546303B (es)
UA (1) UA109698C2 (es)
WO (1) WO2012101239A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2817292B1 (en) 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2014026125A1 (en) * 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134320A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52494A (fr) 2018-05-04 2021-03-10 Incyte Corp Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
EP3788046A1 (en) 2018-05-04 2021-03-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
CN116745268A (zh) 2020-11-20 2023-09-12 2692372安大略公司 苯磺酰胺衍生物及其用途
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
CN100338047C (zh) 2000-06-22 2007-09-19 辉瑞大药厂 吡唑并嘧啶酮类的制备方法
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
CA2620254A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
PL2120932T3 (pl) 2006-12-20 2015-02-27 Nerviano Medical Sciences Srl Indazolowe pochodne jako inhibitory kinazy do leczenia raka
NZ583450A (en) 2007-07-20 2012-05-25 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
UA109698C2 (xx) 2015-09-25
JP2014503574A (ja) 2014-02-13
MY180666A (en) 2020-12-04
CN103339129B (zh) 2015-07-29
TW201247664A (en) 2012-12-01
NZ614432A (en) 2015-03-27
IL227496A0 (en) 2013-09-30
AU2012210467A1 (en) 2013-09-12
KR20140014147A (ko) 2014-02-05
RU2013138624A (ru) 2015-03-10
US20130085144A1 (en) 2013-04-04
MX2013008673A (es) 2013-12-02
TN2013000293A1 (en) 2015-01-20
AU2012210467B2 (en) 2016-07-07
IL257748A (en) 2018-04-30
PT2668184T (pt) 2018-03-13
DK2668184T3 (en) 2018-03-12
PL2668184T3 (pl) 2018-06-29
JP5931926B2 (ja) 2016-06-08
US8883821B2 (en) 2014-11-11
CN103339129A (zh) 2013-10-02
ES2661695T3 (es) 2018-04-03
KR20180122028A (ko) 2018-11-09
LT2668184T (lt) 2018-04-10
FR2970967B1 (fr) 2013-02-15
CY1120088T1 (el) 2018-12-12
US20130172360A1 (en) 2013-07-04
EP2668184A1 (en) 2013-12-04
CA2823824A1 (en) 2012-08-02
KR101923751B1 (ko) 2018-11-29
RS57101B1 (sr) 2018-06-29
TR201802944T4 (tr) 2018-03-21
IL227496B (en) 2019-02-28
HRP20180524T1 (hr) 2018-05-04
EP2668184B1 (en) 2018-01-10
HUE037153T2 (hu) 2018-08-28
CA2823824C (en) 2018-12-11
FR2970967A1 (fr) 2012-08-03
IL257748B (en) 2020-06-30
WO2012101239A1 (en) 2012-08-02
HK1186737A1 (en) 2014-03-21
SI2668184T1 (en) 2018-06-29
MA34903B1 (fr) 2014-02-01
AR084935A1 (es) 2013-07-10
TWI546303B (zh) 2016-08-21
RU2600976C2 (ru) 2016-10-27

Similar Documents

Publication Publication Date Title
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
NZ708593A (en) Novel pyrazole derivative
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX2013012588A (es) Inhibidores de cinasa.
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
WO2011044375A3 (en) Apogossypolone derivatives as anticancer agents
IN2014KN01113A (es)
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.

Legal Events

Date Code Title Description
FG Grant or registration